Drug intelligence / Profile preview

PPMXT001

Development stage: Preclinical
Lead developer: Perseus Proteomics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PPMXT001 is a human monoclonal antibody directed against the transferrin receptor (TfR), a type II transmembrane glycoprotein essential for intracellular iron uptake and cell proliferation. Developed by Perseus Proteomics, the antibody is designed to treat malignancies where TfR is overexpressed, such as pancreatic cancer. PPMXT001 functions by inhibiting the growth of tumor cells and eliciting antibody-dependent cellular cytotoxicity (ADCC). In preclinical studies, it demonstrated potent anti-tumor activity, including the complete suppression of tumor growth in MIAPaCa2 pancreatic cancer xenograft models.

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on PPMXT001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PPMXT001.

Explore the full profile